These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15912653)

  • 1. [Huesca and Teruel survey on hemodialysis management].
    Gascón A; Virto R; Pernaute R; Lou LM; García FJ;
    Nefrologia; 2005; 25(2):163-9. PubMed ID: 15912653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of care assessment and adherence to the international guidelines considering dialysis, water treatment, and protection against transmission of infections in university hospital-based dialysis units in Cairo, Egypt.
    Ibrahim S
    Hemodial Int; 2010 Jan; 14(1):61-7. PubMed ID: 19758297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epidemiological study on chronic renal failure elderly patients on hemodialysis].
    de Francisco AL; Sanjuán F; Foraster A; Fabado S; Carretero D; Santamaría C; Aguilera J; Alcalá MI; Aljama P
    Nefrologia; 2008; 28(1):48-55. PubMed ID: 18336131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional profile and inflammatory status of stable chronic hemodialysis patients at Nephrology Department, Military Hospital Rawalpindi.
    Siddiqui UA; Halim A; Hussain T
    J Ayub Med Coll Abbottabad; 2007; 19(4):29-31. PubMed ID: 18693592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spanish survey on anaemia management].
    Pérez García R
    Nefrologia; 2003; 23(4):300-11. PubMed ID: 14558329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management and treatment response in patients on hemodialysis: the MAR study.
    Portolés J; López-Gómez JM; Aljama P
    J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of the international hemodialysis study DOPPS in Spain and Europe].
    Cruz JM; Piera L; Bragg-Gresham JL; Feldman H; Port FK
    Nefrologia; 2003; 23(5):437-43. PubMed ID: 14658170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
    Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
    Pellicano R; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemodialysis prospective multicentric quality study].
    Parra E; Ramos R; Betriú A; Paniagua J; Belart M; Martín F; Martínez T
    Nefrologia; 2006; 26(6):688-94. PubMed ID: 17227246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a quality improvement strategy on several haemodialysis outcomes.
    Parra E; Ramos R; Betriu A; Paniagua J; Belart M; Martínez T
    Nephrol Dial Transplant; 2008 Sep; 23(9):2943-7. PubMed ID: 18372391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target quantity for twice-a-week hemodialysis: the EKR (equivalent renal urea clearance) approach.
    Manotham K; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S79-85. PubMed ID: 17044458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hypertension and predisposing factors in patients receiving hemodialysis.
    Mousavi SA; Mahdavi-Mazdeh M; Yahyazadeh H; Azadi M; Rahimzadeh N; Yoosefnejad H; Ataiipoor Y
    Iran J Kidney Dis; 2008 Jan; 2(1):29-33. PubMed ID: 19367006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of immutable variables determining rHuEPO dose requirements on hemodialysis patients].
    Gascón A; Virto R; Lou LM; Pernaute R; Moreno R; Pérez J; Aladrén MJ; Moragrega B; Castillón E; Gómez R; Vives PJ; Alvarez R; García FJ; Castilla J; Gutiérrez Colón JA
    Nefrologia; 2005; 25(5):535-42. PubMed ID: 16392304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between C-reactive protein and biomarkers of bone and mineral metabolism in chronic hemodialysis patients: a cross-sectional study.
    Lee CT; Tsai YC; Ng HY; Su Y; Lee WC; Lee LC; Chiou TT; Liao SC; Hsu KT
    J Ren Nutr; 2009 May; 19(3):220-7. PubMed ID: 19243976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.